Mass spectrometry reimagined for smarter, faster drug discovery
What is CARMS?
Collision Activated Rapid Mass Spectrometry (CARMS) is MassAffinity’s proprietary platform for rapidly and accurately identifying drug-target interactions in complex biological systems.
CARMS does what other methods don’t.
It works directly in native samples, with no protein purification, no assay development and no artificial environments.
This allows discovery teams to move faster, reduce risk and uncover interactions that might otherwise go undetected.
How CARMS works
From samples to hits at unmatched speed
CARMS accelerates drug screening into three key steps, all happening within a single instrument
How is CARMS different?
We don’t work around complexity, we cut through it.
Traditional hit identification requires purified proteins, custom assay development and biological systems that do not reflect real biology.
These steps are slow, costly, and often lead to missed or misleading results.
CARMS delivers faster, more accurate hit identification by removing the slowest and most limiting parts of traditional screening while preserving what matters most: real biological context.
What only CARMS can do
No protein purification required
CARMS works directly in cell lysates, eliminating the need for slow, complex protein preparation.
Built-in filtering eliminates false positives
Selective mass detection ensures only true binders are captured.
No custom assays required
There is no need to build custom assays — binding is detected directly using mass spectrometry.
High-throughput, even in complex samples
Highly multiplexed screening in lysates and mixtures without compromising biological fidelity.
Works in real biological context
CARMS captures interactions as they occur in native environments.
Delivers results in weeks, not months
By skipping purification and assay setup, CARMS dramatically reduces early-stage timelines.
Collision energy confirms true binding
Bound complexes are dissociated inside the mass spectrometer using controlled energy, revealing real interactions.
Accelerates discovery 10× over legacy workflows
CARMS technology products
CARMS Products for your discovery needs
Three focused products within the CARMS platform, tailored to support different phases and approaches in early discovery.
How our technology supports the drug discovery pipeline?
The starting point for smarter drug discovery
MassAffinity targets the earliest phase of drug discovery, where many programs stall due to undruggable targets, assay limitations or biological complexity.